Paper8229682
Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective.
D'Argenio DZ and 1 other. J Pharmacokinet Biopharm, 1993. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective. Papers, record 8229682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8229682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Teniposide | Major topic |
| Drug Monitoring | |
| Feedback | |
| Humans | |
| Models, Biological | |
| Population | |
| Treatment Outcome |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 20180 | NCI NIH HHS | United States | P01CA020180 | PubMed and NIH | NIH RePORTER |
| P30 CA21765 | NCI NIH HHS | United States | P30CA021765 | PubMed and NIH | NIH RePORTER |
| P41 RR01861 | NCRR NIH HHS | United States | P41RR001861 | PubMed and NIH | NIH RePORTER |
References11
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1999001 | Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/1999001 | PubMed |
| 2 | 8426206 | Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. | J Clin Oncol | 1993 | https://conductscience.org/library/papers/8426206 | PubMed |
| 3 | 3905164 | Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application. | Clin Pharmacokinet | 1985 | https://conductscience.org/library/papers/3905164 | PubMed |
| 4 | 1137256 | Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. | Ann Intern Med | 1975 | https://conductscience.org/library/papers/1137256 | PubMed |
| 5 | 3297462 | The clinical pharmacology of etoposide and teniposide. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3297462 | PubMed |
| 6 | 7152739 | Methods for evaluating optimal dosage regimens and their application to theophylline. | Int J Clin Pharmacol Ther Toxicol | 1982 | https://conductscience.org/library/papers/7152739 | PubMed |
| 7 | 2134510 | Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. | Math Biosci | 1990 | https://conductscience.org/library/papers/2134510 | PubMed |
| 8 | 3598607 | Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. | J Clin Oncol | 1987 | https://conductscience.org/library/papers/3598607 | PubMed |
| 9 | 6958957 | VM-26 with prednisone and vincristine for treatment of refractory acute lymphocytic leukemia. | Med Pediatr Oncol | 1982 | https://conductscience.org/library/papers/6958957 | PubMed |
| 10 | 529025 | A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters. | J Pharmacokinet Biopharm | 1979 | https://conductscience.org/library/papers/529025 | PubMed |
| 11 | 3806374 | Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics. | J Pharmacokinet Biopharm | 1986 | https://conductscience.org/library/papers/3806374 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37111566 | From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37111566 | PubMed |
| 31481443 | Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31481443 | PubMed |
| 27585476 | A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics. | Clin Pharmacokinet | 2017 | https://conductscience.org/library/papers/27585476 | PubMed |
| 18611060 | Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. | Clin Pharmacokinet | 2008 | https://conductscience.org/library/papers/18611060 | PubMed |
| 10214563 | Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile. | J Pharmacokinet Biopharm | 1998 | https://conductscience.org/library/papers/10214563 | PubMed |
| 7473080 | Comparison of some control strategies for three-compartment PK/PD models. | J Pharmacokinet Biopharm | 1994 | https://conductscience.org/library/papers/7473080 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8229682
GET https://conductscience.org/api/papers/v1/8229682/authors